JP2022523018A5 - - Google Patents
Info
- Publication number
- JP2022523018A5 JP2022523018A5 JP2021542124A JP2021542124A JP2022523018A5 JP 2022523018 A5 JP2022523018 A5 JP 2022523018A5 JP 2021542124 A JP2021542124 A JP 2021542124A JP 2021542124 A JP2021542124 A JP 2021542124A JP 2022523018 A5 JP2022523018 A5 JP 2022523018A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- treatment
- fenebrutinib
- weeks
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024062648A JP2024099575A (ja) | 2019-01-22 | 2024-04-09 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
| JP2025189049A JP2026041743A (ja) | 2019-01-22 | 2025-11-10 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795477P | 2019-01-22 | 2019-01-22 | |
| US62/795,477 | 2019-01-22 | ||
| US201962913270P | 2019-10-10 | 2019-10-10 | |
| US62/913,270 | 2019-10-10 | ||
| PCT/US2020/014346 WO2020154252A1 (en) | 2019-01-22 | 2020-01-21 | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062648A Division JP2024099575A (ja) | 2019-01-22 | 2024-04-09 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523018A JP2022523018A (ja) | 2022-04-21 |
| JP2022523018A5 true JP2022523018A5 (enExample) | 2023-02-01 |
Family
ID=69726724
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542124A Pending JP2022523018A (ja) | 2019-01-22 | 2020-01-21 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
| JP2024062648A Pending JP2024099575A (ja) | 2019-01-22 | 2024-04-09 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
| JP2025189049A Pending JP2026041743A (ja) | 2019-01-22 | 2025-11-10 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024062648A Pending JP2024099575A (ja) | 2019-01-22 | 2024-04-09 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
| JP2025189049A Pending JP2026041743A (ja) | 2019-01-22 | 2025-11-10 | ブルトン型チロシンキナーゼの阻害剤を使用する関節リウマチ、慢性自発性蕁麻疹、および全身性エリテマトーデスの処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12544372B2 (enExample) |
| EP (1) | EP3914250A1 (enExample) |
| JP (3) | JP2022523018A (enExample) |
| KR (1) | KR20210119457A (enExample) |
| CN (3) | CN118453606A (enExample) |
| AU (2) | AU2020213265B2 (enExample) |
| CA (1) | CA3125236A1 (enExample) |
| IL (1) | IL284779A (enExample) |
| MX (2) | MX2021008696A (enExample) |
| TW (1) | TW202042815A (enExample) |
| WO (1) | WO2020154252A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022019846A2 (pt) | 2020-04-03 | 2022-11-22 | Genentech Inc | Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos |
| CN118924759A (zh) * | 2023-05-12 | 2024-11-12 | 武汉人福创新药物研发中心有限公司 | 含有btk抑制剂的组合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013011176A2 (pt) * | 2010-11-05 | 2020-09-01 | Novartis Ag | métodos de tratamento de artrite reumatoide usando antagonistas de il-17 |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| WO2017148837A1 (en) | 2016-02-29 | 2017-09-08 | F. Hoffmann-La Roche Ag | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CN110709702A (zh) | 2017-03-24 | 2020-01-17 | 豪夫迈·罗氏有限公司 | 治疗自身免疫性疾病和炎性疾病的方法 |
-
2020
- 2020-01-21 TW TW109102194A patent/TW202042815A/zh unknown
- 2020-01-21 CN CN202410639156.8A patent/CN118453606A/zh active Pending
- 2020-01-21 CA CA3125236A patent/CA3125236A1/en active Pending
- 2020-01-21 MX MX2021008696A patent/MX2021008696A/es unknown
- 2020-01-21 CN CN202410640589.5A patent/CN118662512A/zh active Pending
- 2020-01-21 KR KR1020217026474A patent/KR20210119457A/ko not_active Ceased
- 2020-01-21 CN CN202080010603.3A patent/CN113423401A/zh active Pending
- 2020-01-21 WO PCT/US2020/014346 patent/WO2020154252A1/en not_active Ceased
- 2020-01-21 EP EP20708271.0A patent/EP3914250A1/en active Pending
- 2020-01-21 AU AU2020213265A patent/AU2020213265B2/en active Active
- 2020-01-21 JP JP2021542124A patent/JP2022523018A/ja active Pending
-
2021
- 2021-07-12 IL IL284779A patent/IL284779A/en unknown
- 2021-07-19 MX MX2025013950A patent/MX2025013950A/es unknown
- 2021-07-21 US US17/381,592 patent/US12544372B2/en active Active
-
2024
- 2024-04-09 JP JP2024062648A patent/JP2024099575A/ja active Pending
-
2025
- 2025-03-17 AU AU2025201888A patent/AU2025201888A1/en active Pending
- 2025-11-10 JP JP2025189049A patent/JP2026041743A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11344545B2 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| US20180117148A1 (en) | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders | |
| JP2013521303A5 (enExample) | ||
| Ayuso Gutierrez et al. | Tryptophan and an MAOI (Nialamide) in the treatment of depression | |
| EP2969001B1 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
| JP6535678B2 (ja) | 視神経脊髄炎を治療するためのクラドリビンの使用 | |
| JP2025502266A (ja) | 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法 | |
| JP2022523018A5 (enExample) | ||
| JPS63243028A (ja) | 基本的うつ病を軽減するためのうつ病治療剤 | |
| CA3188003A1 (en) | Use of btk inhibitors in the treatment of diseases | |
| US20140127295A1 (en) | Compositions, process of preparation of said compositions and method of treating inflammatory diseases | |
| RU2712281C1 (ru) | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма | |
| JP7186214B2 (ja) | 自己免疫性神経筋疾患を処置するためのクラドリビンの使用 | |
| JP2025000672A (ja) | Ｌｏｕ０６４を使用した治療の方法 | |
| CN1646130A (zh) | 类风湿性关节炎的治疗 | |
| CN101048160B (zh) | 嘌呤和嘧啶cdk抑制剂及其在制备用于治疗自身免疫性疾病的药物中的用途 | |
| RU2837046C1 (ru) | Применение ингибиторов btk при лечении заболеваний | |
| RU2854955C1 (ru) | Применение кладрибина для лечения иммунных заболеваний головного мозга | |
| US20130267484A1 (en) | Treatment of rheumatoid arthritis with masitinib | |
| Bloxham | 9.1 Learning Outcomes | |
| WO2025221754A1 (en) | Upadacitinib for use in the treatment of giant cell arteritis | |
| Rejón et al. | Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement | |
| RU2810253C2 (ru) | Способ лечения с применением традипитанта | |
| TW202604505A (zh) | 用烏帕替尼治療巨細胞動脈炎之方法 | |
| WO2010021385A1 (ja) | Ａｎｃａ関連血管炎治療薬 |